# US 2010/0168120 A1 · Salts of pyridazine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168120 A1
- Document ID: US20100168120A1
- Status: Published application
- Kind: A1
- Application number: 12/298,624
- Filed: 2007-04-27
- Published: 2010-07-01
- Earliest claimed: 2006-04-28
- Assignees: Neuromedix Inc.
- Inventors: D.Martin Watterson; Linda Van Eldik; Wenhui Hu
- Web page: https://patentgrep.com/patent/US20100168120A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to stable and substantially purified synthetic pharmaceutically acceptable acid addition salts of pyridazine compounds of the formula I wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, alkynyl, alkylene, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, ═S, carboxyl, carbonyl, carbamoyl, carboxamide, or phosphonate, and R11 is alkyl, alkoxy, alkenyl, alkynyl, alkylene, alkenylene, alkenyloxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, =0, ═S, phosphonate, carboxyl, carbonyl, carbamoyl, carboxamide, or ureido. The invention also relates to formulations, dosage forms and compositions comprising the salts, and methods of using the salts, formulations, dosage forms and compositions.

## Claims

### Claim 1

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salts of a compound of the formula I:
wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, alkynyl, alkylene, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, ═O, ═S, carboxyl, carbonyl, carbamoyl, carboxamide, or phosphonate, and R11 is alkyl, alkoxy, alkenyl, alkynyl, alkylene, alkenylene, alkenyloxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy; thioaryl, nitro, cyano, halo, ═O, ═S, phosphonate carboxyl, carbonyl, carbamoyl, carboxamide, or ureido.

### Claim 2 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, alkenyl, aryl, heteroaryl, sulfonyl, sulfinyl, sulfenyl, amino, thiol, thioalkyl, thioalkoxy, nitro, halo, ═O, ═S, or carboxyl; and R11 is alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl.

### Claim 3 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R10 is hydrogen, hydroxyl, alkyl, alkoxy, sulfonyl, sulfinyl, halo, thiol, or carboxyl, and R11 is alkyl, alkenyl, alkoxy, alkenyloxy, aryl, heteroaryl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, nitro, cyano, halo, ═O, ═S, carboxyl, carbonyl, carbamoyl, or carboxamide; or an isomer or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R11 is hydrogen, alkyl, alkoxy, amino, thiol, halo, ═O, ═S, phosphonate, or carboxyl.

### Claim 5 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein, R11 is alkyl, alkoxy, alkenyl, aryl, or heteroaryl.

### Claim 6 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R11 is alkyl, aryl, or an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms.

### Claim 7 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R11 is alkyl or heteroaryl.

### Claim 8 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein one of R10 and R11 in a compound of the formula I is a heteroaryl.

### Claim 9 (depends on 8)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 8 wherein the heteroaryl is an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms.

### Claim 10 (depends on 8)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 8 wherein one of R10 and R11 is a pyridinyl, and the other of R10 and R11 is hydrogen.

### Claim 11 (depends on 5)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 5 wherein R11 is substituted or substituted alkyl, phenyl, benzyl, or pyridinyl.

### Claim 12 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein one of R10 and R11 in a compound of the formula I is phenyl or benzyl, and the other of R10 and R11 is hydrogen.

### Claim 13 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein one of R10 and R11 in a compound of the formula I is C1-C6 alkyl and the other of R10 and R11 is hydrogen.

### Claim 14 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 wherein R11 in a compound of the formula I is C1-C6 alkyl and R10 is hydrogen.

### Claim 15

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim wherein the salts are halide salts.

### Claim 16

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim wherein the salt is a chloride or bromide salt.

### Claim 17 (depends on 15, 16)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 15 or 16 wherein the counter-cation of the halide salt is an alkali metal or hydrogen.

### Claim 18

A stable and substantially synthetic pharmaceutically acceptable acid addition salt according to any preceding claim wherein the salts are hydrochloride salts.

### Claim 19

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim which is a di-hydrochloride salt.

### Claim 20

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim which is a non-crystalline form.

### Claim 21

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim which is a crystalline chloride or bromide salt of a compound of the formula I.

### Claim 22 (depends on 1)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 1 which is a halide salt of 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine.

### Claim 23 (depends on 22)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 22 which is a chloride salt of 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine.

### Claim 24 (depends on 23)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 23 which is a hydrochloride salt of 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine.

### Claim 25 (depends on 24)

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to claim 24 which is a di-hydrochloride hydrate salt of 2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine.

### Claim 26

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim having a purity of greater than about 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

### Claim 27

A stable and substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim having an aqueous solubility at 37° C. of about 100 to 400 mg/ml, about 100 to 350 mg/ml, about 150 to 350 mg/ml, about 200 to 350 mg/ml, or about 300 to 350 mg/ml.

### Claim 28

A pharmaceutical composition comprising a substantially purified synthetic pharmaceutically acceptable acid addition salt according to any preceding claim and a pharmaceutically acceptable carrier, excipient or vehicle.

### Claim 29

A method for preparing a pharmaceutical composition comprising mixing an acid addition salt of a compound of the formula I according to any preceding claim into a selected pharmaceutical carrier, excipient or vehicle, and optionally adding other therapeutic agents.

### Claim 30

A method for treating a neuroinflammatory disease in a subject comprising administering an effective amount of a salt or composition according to any preceding claim.

### Claim 31

Use of a salt or composition according to any preceding claim in the preparation of a medicament for treating a neuroinflammatory disease.

### Claim 32

A kit comprising one or more acid addition salt of a compound of the formula I, or a composition according to any preceding claim, a container, and instructions for use.
